Pharmacokinetic Profile of Controlled-Release Carvedilol in Patients with Left Ventricular Dysfunction Associated with Chronic Heart Failure or After Myocardial Infarction

American Journal of Cardiology

Volumn 98, Issue 7 SUPPL., 2006, Pages 39-45

  Packer, Milton ^a   Lukas, Mary Ann ^b   Tenero, David M ^b   Baidoo, Charlotte A ^b   Greenberg, Barry H ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG FORMULATION; ENANTIOMER; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CANADA; CARBAZOLES; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPANOLAMINES; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33749118663     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.07.018     Document Type: Article

References (11)

1. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H., and US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996) 1349-1355
2. Packer M., Colucci W.S., Sackner-Bernstein J.D., Liang C.S., Goldscher D.A., Freeman I., Kukin M.L., Kinhal V., Udelson J.E., Klapholz M., et al., PRECISE [Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise] Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation 94 (1996) 2793-2799
3. Colucci W.S., Packer M., Bristow M.R., Gilbert E.M., Cohn J.N., Fowler M.B., Krueger S.K., Hershberger R., Uretsky B.F., Bowers J.A., et al., US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 94 (1996) 2800-2806
4. Packer M., Coats A.J., Fowler M.B., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Castaigne A., Roecker E.B., Schultz M.K., and DeMets D.L. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
5. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357 (2001) 1385-1390
6. 1-receptor?. A perspective on the results of the COMET trial. J Card Fail 9 (2003) 429-443
7. Claxton A.J., Cramer J., and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23 (2001) 1296-1310
8. Iskedjian M., Einarson T.R., MacKeigan L.D., Shear N., Addis A., Mittmann N., and Ilersich A.L. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 24 (2002) 302-316
9. Wetzels G.E., Nelemans P., Schouten J.S., and Prins M.H. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 22 (2004) 1849-1855
10. Tu W., Morris A.B., Li J., Wu J., Young J., Brater D.C., and Murray M.D. Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. Clin Pharmacol Ther 77 (2005) 189-201
11. Richter A., Anton S.E., Koch P., and Dennett S.L. The impact of reducing dose frequency on health outcomes. Clin Ther 25 (2003) 2307-2335